![]() GlycoMimetics GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers. | ![]() Iovance Biotherapeutics Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. | Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. | |
Founding Date | Founding Date 2003 | Founding Date 2013 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Rockville, US HQ | Locations San Carlos, US HQ New York, US Philadelphia, US Philadelphia, US Tampa, US | |
Employees | Employees 5025% increase | Employees 14868% increase | Employees 5,669 |
Valuation ($) | Valuation ($) 31.6 m | Valuation ($) 3.3 b | Valuation ($) 8.8 b |
Financial | |||
Revenue (est.) | Revenue (est.) $10.8m (FY, 2025) | Revenue (est.) $263.5m (FY, 2025) | Revenue (est.) ¥496.8b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $173.2m (FY, 2025) | Cost of goods ¥114.3b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $90.3m (FY, 2025) | Gross profit ¥383.4b (FY, 2025) |
Net income | Net income ($153.9m) (FY, 2025) | Net income N/A | Net income ¥67b (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 101.8m | Total funding raised $ 100m | Total funding raised N/A |

Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes.
View companyKyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View company